RealFeedApp beta
- U.S. Patent No. 12,759,979 expires in 2045
The patent protects a novel crystalline form of zervimesine for treating Alzheimer's and dementia with Lewy bodies. The drug is currently in Phase 2 clinical trials.
- Field
- ageing and longevity
- What they did
- Cognition Therapeutics received a patent for a novel crystalline form of the drug zervimesine (CT1812), intended to treat Alzheimer's disease, dementia with Lewy bodies, and age-related macular degeneration.
- Why it matters
- The patent protects the specific composition and production process of the drug, extending its commercial protection until 2045 and potentially adding up to five more years upon FDA approval.
#zervimesine#patent#alzheimer's#clinical trial#cognition therapeutics
